Skp to main content
29 Apr 2021
UCB's General Meeting of Shareholders 2021
Read More
28 Apr 2021
UCB Announces PDUFA Date for Bimekizumab
Read More
23 Apr 2021
Acquisitions of own shares and disposals of own shares
Read More
23 Apr 2021
UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021
Read More
23 Apr 2021
The New England Journal of Medicine Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis
Read More
22 Apr 2021
UCB’s zilucoplan shows no relevant effect in immune-mediated necrotizing myopathy (IMNM)
Read More
20 Apr 2021
Acquisitions of own shares and Disposals of own shares
Read More
16 Apr 2021
UCB showcases new research at the 73rd American Academy of Neurology Annual Meeting to demonstrate broad neurology leadership and future portfolio
Read More
14 Apr 2021
Notice of Early Redemption - €350 million € 1.875% fixed rate notes due 2 April 2022
Read More
9 Apr 2021
Acquisitions of own shares and Disposals of own shares
Read More
Subscribe to
